Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Mar;13(2):259-260.
doi: 10.1177/1932296818811672. Epub 2018 Nov 19.

Analysis of "Performance of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System in Pediatric Participants With Type 1 Diabetes"

Affiliations
Comment

Analysis of "Performance of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System in Pediatric Participants With Type 1 Diabetes"

Ralph Ziegler. J Diabetes Sci Technol. 2019 Mar.

Abstract

Accuracy of sensors play an important role in the acceptance and long-term use of CGM which is related to improved glycemic outcome. This has been lower in children and adolescents in the past for reasons such as size of the device, pain, and necessity to calibrate sensors but also inaccuracy and perceived nonreliability on alarms among others. In the study of Welsh et al, performance of a new, factory-calibrated sensor was assessed. The accuracy of the sensor, as measured in MARD, paired values within 20/20% or 15/15% and surveillance error grid analysis showed very good results, although less so in low value range <70 mg/dL, falling rate of change, and on first day of use. Accurate glucose measurements especially in these incidences are of utmost importance to people with diabetes as their treatment decisions are based on these, also in the beginning of sensor use.

Keywords: MARD; advanced algorithm; clinical accuracy; continuous glucose monitoring; factory calibrated; glucose sensor performance.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The author has received lecture honoraria from Animas, Novo Nordisk, and Roche Diabetes Care and is member of Advisory Boards for Abbott, Ascensia, AstraZeneca, Lilly, Novo Nordisk, and Roche Diabetes Care

Comment on

References

    1. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359(14):1464-1476. - PubMed
    1. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Beck RW, Buckingham B, et al. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2009;32(11):1947-1953. - PMC - PubMed
    1. Mauras N, Beck R, Xing D, et al. A randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to <10 years. Diabetes Care. 2012;35(2):204-210. - PMC - PubMed
    1. Klonoff DC, Kerr D. A simplified approach using rate of change arrows to adjust insulin with real-time continuous glucose monitoring. J Diabetes Sci Technol. 2017;11(6):1063-1069. - PMC - PubMed
    1. Laffel LM, Aleppo G, Buckingham BA, et al. A practical approach to using trend arrows on the Dexcom G5 CGM system to manage children and adolescents with diabetes. J Endocr Soc. 2017;1(12):1461-1476. - PMC - PubMed